Prestige Consumer Healthcare

Prestige Consumer Healthcare delivered a 6.5% increase in sales (3.2% organic) and $0.98 adjusted diluted EPS, up 3%, during the first fiscal quarter of 2027. Both figures were above FactSet consensus. Raised guidance reflects Breathe Right and LaCorium acquisitions. Shares traded flat on Aug. 6.

Why it matters: We see fiscal 2027 as a major transition year for Prestige as the firm brings on new brands to its domestic and international portfolios. Breathe Right and LaCorium Health acquisitions both closed during the quarter and should contribute a combined $240 million in revenue on an annualized basis. Prestige paid $1 billion for Breathe Right, making it the firm's largest acquisition to date. Prestige has a long track record of expanding its portfolio with tuck-ins, so we think integration efforts should be fairly smooth. Clear Eyes issues, which have been ongoing for well over a year, still have not been remediated. The addition of Pillar5 from last year should help with recovery, but we don't expect any sudden uptick in consumption in the near term.

The bottom line: We reiterate our $70 fair value estimate for narrow-moat Prestige and see shares, trading in the mid-50s on Aug. 6, as materially undervalued with about 23% upside. Our valuation reflects 10.1 times enterprise value/2027 adjusted EBITDA. We think investors are staying cautious for now as Prestige traverses through the year with major investments behind it. Readouts from the next few quarters look particularly important for the stock as the market assesses how well Prestige executes in new categories with new brands. We're also paying close attention to margins for the remainder of the year. Breathe Right's 70% gross margin looks attractive against Prestige's typical high-50s adjusted level, adding to our favorable stance on the acquisition. But realizing the full margin accretion will depend on market conditions and commercial success.

We lower our fair value estimate to $70 per share from $77 for narrow-moat Prestige. Fiscal 2027 guidance includes 2% organic sales and EPS growth, both of which are lower than we had anticipated. Given the weak exit to the year and the firm's track record of lowering guidance throughout fiscal 2026, our estimates are on the lower end of the guidance range. Our forecast model has a five-year revenue CAGR of roughly 2% and a gradual year-over-year margin ramp-up. Our valuation reflects an EV/2027 EBITDA multiple of 11.

Prestige leads in many categories it serves, including motion sickness relief, vaginal antifungal remedies, and pharyngeal preparations. While these categories are small and niche, we think they will still grow in the low single digits over our forecast period, driven by industrywide trends, including an aging population, increasing focus on consumer health, and a premiumization of self-care. We also think that primarily playing in niche categories can somewhat mitigate pressure from private-label and larger OTC players, given their limited market size. We view the likelihood of a big manufacturer spending time and resources to launch a new product and displace Prestige’s products in these markets as low, given that they play in larger categories with a significantly larger addressable market.

In the long term, we forecast a low-single-digit top-line growth with a slight improvement in gross margin from supply chain efficiencies and manufacturing productivity improvements. We think the higher gross margin will be somewhat offset by elevated advertising and marketing spending, as we expect competition in consumer healthcare to intensify over the next five years due to large pure-play manufacturers such as Kenvue and Haleon entering the market in recent years.

We assign Prestige Consumer Healthcare a narrow moat rating because we believe the company’s strong brand reputation and pricing power (intangible assets) should continue to support economic profits for the next 10 years.

Over 80% of Prestige’s total sales are derived from its portfolio of 18 major brands. Many of Prestige’s brands play in niche categories—Boudreaux’s Butt Paste is baby ointment used to treat diaper rash, Debrox is an earwax removal drop, and Monistat is a vaginal anti-fungal cream. While we believe Prestige lags consumer health giants like Kenvue and Haleon in broad product channels such as analgesics, cough remedies, and oral care, we believe the company has successfully carved out a meaningful presence in smaller unique categories and garnered impressive market share. Prestige’s brands have also held their market leadership for over a decade, demonstrating stability of their market share. Lastly, Prestige’s brands do not have a meaningful competitor in most markets, and the rest of the space is shared among private-label brands that have failed to amass significant shares.

Many of Prestige’s brands come at a moderate to significant pricing premium when compared with its close competitors and that premium is magnified when compared with private label. But even at higher prices, we see that consumers continue to choose Prestige’s brands over its competitors’. One of the main reasons behind Prestige’s market leadership, in our opinion, is the significant brand power and customer loyalty that its brands have amassed with decades of history on the shelf and inside people’s homes. We also believe a number of Prestige’s brands are sought out in times of poor health, so the importance of brand familiarity and trust is heightened. And because Prestige’s brands are backed by years of scientific research, they benefit from recommendations of professionals across its mix of products. For example, Dramamine is the number one pharmacist-recommended brand for motion sickness, and Monistat is the number one gynecologist-recommended brand for vaginal anti-fungal remedies. The leading market shares in many of the categories it plays in, even at higher prices, illustrate Prestige’s strong brand reputation and high levels of consumer trust and loyalty.

To ensure its brand prowess and maintain its leading position, Prestige continues to innovate and launch new products to align with ever-changing consumer preferences. We estimate that the firm spends a low-single-digit percentage of sales on research and development and 15% on advertising and marketing, on par with its competitors Kenvue (4% and 10% of sales on R&D and A&M, respectively) and Procter & Gamble (3% and 11%, respectively). We believe Prestige can maintain its leading share position and entrenched standing with retailers through product innovation over the next 10 years thanks to its strong brand power and innovations.

Prestige is well positioned to enjoy macro long-term trends, including aging population, rising awareness of self-care, and premiumization of consumer healthcare.

Prestige’s portfolio is filled with category-leading brands, and we believe it can increase its household penetration and bolster its brand equity through more research and innovation.

By focusing on small and niche markets, we believe Prestige is more insulated from private-label entry compared with products that play in larger categories.

Emerging large players in the consumer healthcare space, including Haleon and Kenvue, have the resources to expand their portfolios and displace smaller brands that Prestige owns.

Prestige spends less as a percentage of sales on research and development compared with larger competitors in the space, which could make the company susceptible to fall out of ever-changing consumer preferences.

Mismanagement in production could lead to product recalls and result in large settlement fees, putting pressure on Prestige’s bottom line.